+

WO2006046734A3 - オーロラa選択的阻害作用を有する新規アミノピリジン誘導体 - Google Patents

オーロラa選択的阻害作用を有する新規アミノピリジン誘導体 Download PDF

Info

Publication number
WO2006046734A3
WO2006046734A3 PCT/JP2005/019957 JP2005019957W WO2006046734A3 WO 2006046734 A3 WO2006046734 A3 WO 2006046734A3 JP 2005019957 W JP2005019957 W JP 2005019957W WO 2006046734 A3 WO2006046734 A3 WO 2006046734A3
Authority
WO
WIPO (PCT)
Prior art keywords
represent
hydrogen
inhibitory effect
anticancer agent
same
Prior art date
Application number
PCT/JP2005/019957
Other languages
English (en)
French (fr)
Other versions
WO2006046734A1 (ja
WO2006046734A2 (ja
Inventor
Mitsuru Ohkubo
Tetsuya Kato
Nobuhiko Kawanishi
Takashi Mita
Toshiyasu Shimomura
Original Assignee
Banyu Pharma Co Ltd
Mitsuru Ohkubo
Tetsuya Kato
Nobuhiko Kawanishi
Takashi Mita
Toshiyasu Shimomura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd, Mitsuru Ohkubo, Tetsuya Kato, Nobuhiko Kawanishi, Takashi Mita, Toshiyasu Shimomura filed Critical Banyu Pharma Co Ltd
Priority to EP05799135.8A priority Critical patent/EP1813609B1/en
Priority to AU2005297848A priority patent/AU2005297848B2/en
Priority to CA2585638A priority patent/CA2585638C/en
Priority to JP2006542361A priority patent/JP4973190B2/ja
Priority to US11/666,531 priority patent/US20080027042A1/en
Publication of WO2006046734A1 publication Critical patent/WO2006046734A1/ja
Publication of WO2006046734A2 publication Critical patent/WO2006046734A2/ja
Priority to PCT/JP2006/311179 priority patent/WO2006129842A1/ja
Publication of WO2006046734A3 publication Critical patent/WO2006046734A3/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PCT/JP2005/019957 2004-10-29 2005-10-25 オーロラa選択的阻害作用を有する新規アミノピリジン誘導体 WO2006046734A2 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP05799135.8A EP1813609B1 (en) 2004-10-29 2005-10-25 Novel aminopyridine derivatives having selective aurora-a inhibitory effect
AU2005297848A AU2005297848B2 (en) 2004-10-29 2005-10-25 Novel aminopyridine derivatives having selective Aurora-A inhibitory effect
CA2585638A CA2585638C (en) 2004-10-29 2005-10-25 Aminopyridine derivatives having aurora a selective inhibitory action
JP2006542361A JP4973190B2 (ja) 2004-10-29 2005-10-25 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
US11/666,531 US20080027042A1 (en) 2004-10-29 2005-10-25 Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action
PCT/JP2006/311179 WO2006129842A1 (ja) 2005-06-01 2006-05-30 オーロラa選択的阻害作用を有する新規アミノピリジン誘導体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004-315152 2004-10-29
JP2004315152 2004-10-29
JP2005-161156 2005-06-01
JP2005161156 2005-06-01

Publications (3)

Publication Number Publication Date
WO2006046734A1 WO2006046734A1 (ja) 2006-05-04
WO2006046734A2 WO2006046734A2 (ja) 2006-05-04
WO2006046734A3 true WO2006046734A3 (ja) 2006-09-21

Family

ID=36227968

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2005/019957 WO2006046734A2 (ja) 2004-10-29 2005-10-25 オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
PCT/JP2005/019958 WO2006046735A1 (en) 2004-10-29 2005-10-25 Novel aminopyridine derivatives having aurora a selective inhibitory action

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/019958 WO2006046735A1 (en) 2004-10-29 2005-10-25 Novel aminopyridine derivatives having aurora a selective inhibitory action

Country Status (19)

Country Link
US (1) US20080027042A1 (ja)
EP (2) EP1828165B1 (ja)
JP (1) JP4973190B2 (ja)
KR (1) KR20070072562A (ja)
AR (1) AR051467A1 (ja)
AU (1) AU2005297848B2 (ja)
BR (1) BRPI0518068A (ja)
CA (1) CA2585638C (ja)
CR (1) CR9066A (ja)
DO (1) DOP2005000218A (ja)
EC (1) ECSP077417A (ja)
IL (1) IL182684A0 (ja)
MA (1) MA29042B1 (ja)
MX (1) MX2007005155A (ja)
NO (1) NO20072688L (ja)
NZ (1) NZ554441A (ja)
PE (1) PE20060600A1 (ja)
TW (1) TW200621759A (ja)
WO (2) WO2006046734A2 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528731B (zh) * 2006-08-31 2014-05-07 Msdk.K.公司 具有 AuroraA选择性抑制作用的氨基吡啶衍生物

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491720B2 (en) * 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
WO2006129842A1 (ja) * 2005-06-01 2006-12-07 Banyu Pharmaceutical Co., Ltd. オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
EP1906948A4 (en) 2005-07-18 2010-03-17 Bipar Sciences Inc TREATMENT OF CANCER
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2007244183B2 (en) * 2006-04-27 2012-05-10 Msd K.K. Novel aminopyridine derivative having aurora-a-selective inhibitory activity
WO2007132221A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combined anticancer pyrimidine-thiazole aurora kinase inhibitors
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
CA2662337A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
AU2007292387A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
GB0619342D0 (en) * 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
WO2008147626A2 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
WO2009064738A2 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
JP5411152B2 (ja) * 2008-02-22 2014-02-12 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
JP5683462B2 (ja) * 2008-07-24 2015-03-11 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ オーロラキナーゼ阻害剤および抗増殖剤を含む治療用組み合わせ
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
KR20110131302A (ko) 2009-03-23 2011-12-06 엠에스디 가부시키가이샤 오로라 ａ 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체
SG178867A1 (en) 2009-08-24 2012-04-27 Neuralstem Inc Synthesis of a neurostimulative piperazine
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
TWI693218B (zh) * 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光ａ激酶抑制劑

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057259A2 (en) * 2000-12-21 2002-07-25 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2003509342A (ja) * 1999-09-10 2003-03-11 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
WO2006008874A1 (ja) * 2004-05-21 2006-01-26 Banyu Pharmaceutical Co., Ltd. アミノチアゾール骨格を有するＣｄｋ４，６選択的阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US20020065270A1 (en) * 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
EA012112B1 (ru) * 2004-05-14 2009-08-28 Миллениум Фармасьютикалз, Инк. Соединения и способы для ингибирования митотической прогрессии
US7491720B2 (en) * 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509342A (ja) * 1999-09-10 2003-03-11 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
WO2002057259A2 (en) * 2000-12-21 2002-07-25 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2006008874A1 (ja) * 2004-05-21 2006-01-26 Banyu Pharmaceutical Co., Ltd. アミノチアゾール骨格を有するＣｄｋ４，６選択的阻害剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528731B (zh) * 2006-08-31 2014-05-07 Msdk.K.公司 具有 AuroraA选择性抑制作用的氨基吡啶衍生物

Also Published As

Publication number Publication date
EP1813609A4 (en) 2010-11-17
EP1813609B1 (en) 2013-06-19
EP1813609A2 (en) 2007-08-01
EP1828165B1 (en) 2013-03-20
JP4973190B2 (ja) 2012-07-11
WO2006046735A1 (en) 2006-05-04
EP1828165A1 (en) 2007-09-05
CA2585638A1 (en) 2006-05-04
AU2005297848B2 (en) 2011-03-17
NZ554441A (en) 2009-07-31
EP1828165A4 (en) 2010-11-10
BRPI0518068A (pt) 2008-10-28
NO20072688L (no) 2007-07-16
IL182684A0 (en) 2007-09-20
AU2005297848A1 (en) 2006-05-04
CA2585638C (en) 2014-05-06
KR20070072562A (ko) 2007-07-04
AR051467A1 (es) 2007-01-17
TW200621759A (en) 2006-07-01
PE20060600A1 (es) 2006-07-14
MX2007005155A (es) 2007-06-26
CR9066A (es) 2007-10-01
DOP2005000218A (es) 2006-05-31
MA29042B1 (fr) 2007-11-01
US20080027042A1 (en) 2008-01-31
ECSP077417A (es) 2007-05-30
WO2006046734A2 (ja) 2006-05-04
JPWO2006046734A1 (ja) 2008-05-22

Similar Documents

Publication Publication Date Title
WO2006046734A1 (ja) オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
WO2006046734A3 (ja) オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
EP1889842A4 (en) HETEROCYCLIC CONNECTION
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2007056159A3 (en) Hydrazone derivatives and uses thereof
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
EP1864665A4 (en) IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
IL174665A0 (en) Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
AU2001235844A1 (en) Imidazol-2-carboxamide derivatives as raf kinase inhibitors
RS54618B1 (en) NEW S-NITROZOGLUTATION REDUCTASE INHIBITORS
WO2007002313A3 (en) Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
SE0400284D0 (sv) Novel compounds
RS51226B (sr) Derivati azapeptida kao inhibitori hiv proteaze
WO2008156094A1 (ja) ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
WO2004014388A8 (en) 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
WO2004110995A8 (en) N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
MX2009007954A (es) Derivado de heterocicliden-n-(aril) acetamida.
WO2007025880A3 (en) Pyrazolone derivatives as 11-beta hsd1 inhibitors
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV LY MD MG MK MN MW MX MZ NA NG NO NZ OM PG PH PL PT RO RU SC SD SG SK SL SM SY TJ TM TN TR TT TZ UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IS IT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006542361

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2585638

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11666531

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005297848

Country of ref document: AU

Ref document number: 2005799135

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3927/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005297848

Country of ref document: AU

Date of ref document: 20051025

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005297848

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580045564.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005799135

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11666531

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载